Ascletis, Inc.
1785 Jianghai Road,building No.1
Suite 804
Binjiang District
Hangzhou
China
Tel: +86-571-8538-9729
Website: http://ascletis.com.cn/
75 articles with Ascletis, Inc.
-
Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index
2/27/2023
Ascletis Pharma Inc. announces that it will be included in the Hang Seng Hong Kong-Listed Biotech Index, effective from March 13, 2023.
-
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
1/31/2023
Ascletis Pharma Inc. announces that the U.S. Food and Drug Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus infection.
-
Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19
1/16/2023
Ascletis Pharma Inc. announces dosing of 4 healthy subjects of the first cohort in multiple-dose escalation Phase I clinical trial of oral 3-chymotrypsin like protease inhibitor ASC11 in combination with 100 mg ritonavir tablets for COVID-19.
-
Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints
1/2/2023
Ascletis Pharma Inc. was recently informed that on December 29, 2022, Viking Therapeutics, Inc., a pharmaceutical company in the United States, filed certain complaints against Ascletis, its founder Dr. Jinzi Jason WU and certain subsidiaries of Ascletis in connection with the drug candidates ASC41 and ASC43F.
-
Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives
12/19/2022
Ascletis Pharma Inc. announces that it has received the Notice of Issuance from the United States Patent and Trademark Office for the patent application of oral viral polymerase inhibitor ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus and respiratory syncytial virus.
-
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
12/7/2022
Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19.
-
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
11/30/2022
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the completion of 180 patient enrollment for the Phase II clinical trial of ASC40 (denifanstat) for treatment of moderate to severe acne. The study is currently still blind.
-
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
11/23/2022
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19.
-
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19
10/10/2022
Ascletis Pharma Inc. announces dosing of 24 healthy subjects of the first 3 cohorts in multiple-dose escalation Phase I clinical trial of oral RNA-dependent RNA polymerase inhibitor ASC10 for COVID-19 at the National Medical Center for Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University.
-
Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH
10/5/2022
Ascletis Pharma Inc. announces dosing of the first patient in the 52-week Phase II clinical trial of thyroid hormone receptor β agonist ASC41 for treatment of liver biopsy-proven non-alcoholic steatohepatitis patients.
-
Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection
9/15/2022
Ascletis Pharma Inc. announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus infection has completed the enrollment of 15 HIV infected patients.
-
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients
8/3/2022
Ascletis Pharma Inc. announces that the U.S. Food and Drug Administration has approved its Investigational New Drug application for ASC10, an oral drug candidate targeting RNA-dependent RNA polymerase for COVID-19, to conduct the Phase Ib clinical trial in mild-to-moderate COVID-19 patients.
-
For the first time in two years, the European Association for the Study of the Liver’s International Liver Congress was back on-site with cutting-edge research in hepatology and other sectors.
-
Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
6/8/2022
This approval from U.S. FDA enables Gannex to complete a critical drug-drug interaction (DDI) study to support upcoming Phase III trials in China, the U.S. and European Union.
-
Two investigational drugs have been taking the spotlight recently from Revive and Ascletis as they share news regarding their potential treatment against COVID-19.
-
Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors
4/6/2022
Ascletis Pharma Inc. announces that the Investigational New Drug application of its second fatty acid synthase inhibitor ASC60 for treatment of advanced solid tumors has been approved by China National Medical Products Administration.
-
Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
3/30/2022
Ascletis Pharma Inc. announces the completion of patient enrollment in the Phase II clinical trial of ASC42 for chronic hepatitis B indication.
-
AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.
-
Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year
3/13/2022
Ascletis Pharma Inc. announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the domestic and global demands.
-
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients
2/14/2022
Ascletis Pharma Inc. announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 in combination with Chidamide in patients infected by human immunodeficiency virus with antiviral suppression.